Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $7.36M rose 61.5% year over year, behind the +73.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.3% from the prior quarter. Over 3 fiscal years it compounded at +248.9% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +61.5% toward the trailing-twelve-month pace of +73.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 19.32M USD
- Year-over-year change
- +70.5%
- 4-year CAGR
- +294.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.32M | +70.5% |
| FY2024 | 2024-12-31 | 11.34M | +124.0% |
| FY2023 | 2023-12-31 | 5.06M | +1012.1% |
| FY2022 | 2022-12-31 | 455K | +468.8% |
| FY2021 | 2021-12-31 | 80K | — |
Stock-Based Compensation vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 stock-based compensation of $25.03M is the 3rd largest of the 7 companies compared; the peer median is $16.07M.
- Its year-over-year change of +73.0% is the 2nd highest of 7, against a peer median of +42.0%.
- Over three fiscal years its annual growth of +248.9% compares with a peer median of +36.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $72.84M | +70.9% | +5.6% | 11.2% | |
| LTM Jun 2026 | $49.78M | +71.5% | +62.2% | — | |
| LTM Jun 2026 | $25.03M | +73.0% | +248.9% | — | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
| LTM Mar 2026 | $11.86M | +7.9% | +52.0% | 36.3% | |
| LTM Mar 2026 | $2.79M | +13.0% | +36.8% | — | |
| LTM Mar 2026 | $2.1M | -12.1% | +36.1% | — | |
| Peer median (excluding MLYS) | $16.07M | +42.0% | +36.5% | 36.3% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 80K | 455K | 5.06M | 11.34M | 19.32M |
| Change in Working Capital | 4.09M | 772K | (7.47M) | 9.52M | 2.73M |
| Accounts Receivables | 0 | 0 | (355K) | 424K | (166K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.09M | 772K | (7.12M) | 9.1M | 2.9M |
| Other Non-Cash Items | 684K | (649K) | (6.87M) | (9.41M) | (9.88M) |
| Operating Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.31M) | (142.42M) |
| Capital Expenditures | 0 | 0 | 0 | (96K) | (15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (71.76M) | (347.97M) | (373.45M) | (814.74M) |
| Sales of Investments | 0 | 50M | 187.5M | 488.5M | 425M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (21.76M) | (160.47M) | 114.96M | (389.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 23.81M | 0 | 202.99M | 116.06M | 591M |
| Common Stock Repurchased | 0 | (1.63M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 258K | 83K | 0 |
| Financing Cash Flow | 23.81M | 128.02M | 203.25M | 116.14M | 591M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.25M | 77.04M | (38.4M) | 64.79M | 58.83M |
| Free Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.41M) | (142.43M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.